 | • レポートコード：GIR-105X04990 • 出版社/出版日： / 2021年5月 • レポート形態：英文、PDF、101ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：Pharma & Healthcare |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、樹状細胞・腫瘍細胞がんワクチンのグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。樹状細胞・腫瘍細胞がんワクチンの種類別市場規模（CD4、CD8、HER-2、Tヘルパー細胞、その他）、用途別市場規模（神経膠芽細胞腫がん、前立腺がん、膵臓がん、結腸直腸がん、腎がん、肺がん、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・樹状細胞・腫瘍細胞がんワクチンの市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：JW CreaGene、Miltenyi Biotec、GlaxoSmithKline、NorthWest BioTherapeutics、ImmunoCellular Therapeutics、EnoChian Bioscience、Medigene、Tella Incorporation ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：CD4、CD8、HER-2、Tヘルパー細胞、その他 ・用途別分析2016年-2026年：神経膠芽細胞腫がん、前立腺がん、膵臓がん、結腸直腸がん、腎がん、肺がん、その他 ・樹状細胞・腫瘍細胞がんワクチンの北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・樹状細胞・腫瘍細胞がんワクチンのヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・樹状細胞・腫瘍細胞がんワクチンのアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・樹状細胞・腫瘍細胞がんワクチンの南米市場規模2016年-2026年：ブラジル、アルゼンチン ・樹状細胞・腫瘍細胞がんワクチンの中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Dendritic Cell and Tumor Cell Cancer Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Dendritic Cell and Tumor Cell Cancer Vaccine size is estimated to be xx million in 2020 from USD xx million in 2019, with a change of XX% between 2019 and 2020. The global Dendritic Cell and Tumor Cell Cancer Vaccine market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Dendritic Cell and Tumor Cell Cancer Vaccine market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
CD 4
CD 8
HER-2
T-helper cell
Others
Market segment by Application can be divided into
Glioblastoma Cancer
Prostate Cancer
Pancreatic Cancer
Colorectal Cancer
Renal Cancer
Lung Cancer
Others
The key market players for global Dendritic Cell and Tumor Cell Cancer Vaccine market are listed below:
JW CreaGene
Miltenyi Biotec
GlaxoSmithKline
NorthWest BioTherapeutics
ImmunoCellular Therapeutics
EnoChian Bioscience
Medigene
Tella Incorporation
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
1 Market Overview
1.1 Dendritic Cell and Tumor Cell Cancer Vaccine Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 CD 4
1.2.3 CD 8
1.2.4 HER-2
1.2.5 T-helper cell
1.2.6 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Glioblastoma Cancer
1.3.3 Prostate Cancer
1.3.4 Pancreatic Cancer
1.3.5 Colorectal Cancer
1.3.6 Renal Cancer
1.3.7 Lung Cancer
1.3.8 Others
1.4 Global Dendritic Cell and Tumor Cell Cancer Vaccine Market Size & Forecast
1.4.1 Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Value (2016-2026))
1.4.2 Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume (2016-2026)
1.4.3 Global Dendritic Cell and Tumor Cell Cancer Vaccine Price by Type (2016-2026) & (USD/Unit)
1.5 Global Dendritic Cell and Tumor Cell Cancer Vaccine Production Capacity Analysis
1.5.1 Global Dendritic Cell and Tumor Cell Cancer Vaccine Total Production Capacity (2016-2026)
1.5.2 Global Dendritic Cell and Tumor Cell Cancer Vaccine Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Dendritic Cell and Tumor Cell Cancer Vaccine Market Drivers
1.6.2 Dendritic Cell and Tumor Cell Cancer Vaccine Market Restraints
1.6.3 Dendritic Cell and Tumor Cell Cancer Vaccine Trends Analysis
2 Manufacturers Profiles
2.1 JW CreaGene
2.1.1 JW CreaGene Details
2.1.2 JW CreaGene Major Business
2.1.3 JW CreaGene Dendritic Cell and Tumor Cell Cancer Vaccine Product and Services
2.1.4 JW CreaGene Dendritic Cell and Tumor Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.2 Miltenyi Biotec
2.2.1 Miltenyi Biotec Details
2.2.2 Miltenyi Biotec Major Business
2.2.3 Miltenyi Biotec Dendritic Cell and Tumor Cell Cancer Vaccine Product and Services
2.2.4 Miltenyi Biotec Dendritic Cell and Tumor Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.3 GlaxoSmithKline
2.3.1 GlaxoSmithKline Details
2.3.2 GlaxoSmithKline Major Business
2.3.3 GlaxoSmithKline Dendritic Cell and Tumor Cell Cancer Vaccine Product and Services
2.3.4 GlaxoSmithKline Dendritic Cell and Tumor Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.4 NorthWest BioTherapeutics
2.4.1 NorthWest BioTherapeutics Details
2.4.2 NorthWest BioTherapeutics Major Business
2.4.3 NorthWest BioTherapeutics Dendritic Cell and Tumor Cell Cancer Vaccine Product and Services
2.4.4 NorthWest BioTherapeutics Dendritic Cell and Tumor Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.5 ImmunoCellular Therapeutics
2.5.1 ImmunoCellular Therapeutics Details
2.5.2 ImmunoCellular Therapeutics Major Business
2.5.3 ImmunoCellular Therapeutics Dendritic Cell and Tumor Cell Cancer Vaccine Product and Services
2.5.4 ImmunoCellular Therapeutics Dendritic Cell and Tumor Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.6 EnoChian Bioscience
2.6.1 EnoChian Bioscience Details
2.6.2 EnoChian Bioscience Major Business
2.6.3 EnoChian Bioscience Dendritic Cell and Tumor Cell Cancer Vaccine Product and Services
2.6.4 EnoChian Bioscience Dendritic Cell and Tumor Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.7 Medigene
2.7.1 Medigene Details
2.7.2 Medigene Major Business
2.7.3 Medigene Dendritic Cell and Tumor Cell Cancer Vaccine Product and Services
2.7.4 Medigene Dendritic Cell and Tumor Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
2.8 Tella Incorporation
2.8.1 Tella Incorporation Details
2.8.2 Tella Incorporation Major Business
2.8.3 Tella Incorporation Dendritic Cell and Tumor Cell Cancer Vaccine Product and Services
2.8.4 Tella Incorporation Dendritic Cell and Tumor Cell Cancer Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019-2021e)
3 Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Manufacturer
3.1 Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Dendritic Cell and Tumor Cell Cancer Vaccine
3.4 Market Concentration Rate
3.4.1 Top 3 Dendritic Cell and Tumor Cell Cancer Vaccine Manufacturer Market Share
3.4.2 Top 6 Dendritic Cell and Tumor Cell Cancer Vaccine Manufacturer Market Share
3.5 Global Dendritic Cell and Tumor Cell Cancer Vaccine Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Dendritic Cell and Tumor Cell Cancer Vaccine Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Dendritic Cell and Tumor Cell Cancer Vaccine Market Size by Region
4.1.1 Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume by Region (2016-2026)
4.1.2 Global Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Region (2016-2026)
4.2 North America Dendritic Cell and Tumor Cell Cancer Vaccine Revenue (2016-2026)
4.3 Europe Dendritic Cell and Tumor Cell Cancer Vaccine Revenue (2016-2026)
4.4 Asia-Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Revenue (2016-2026)
4.5 South America Dendritic Cell and Tumor Cell Cancer Vaccine Revenue (2016-2026)
4.6 Middle East and Africa Dendritic Cell and Tumor Cell Cancer Vaccine Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume by Type (2016-2026)
5.2 Global Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Type (2016-2026)
5.3 Global Dendritic Cell and Tumor Cell Cancer Vaccine Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume by Application (2016-2026)
6.2 Global Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Application (2016-2026)
6.3 Global Dendritic Cell and Tumor Cell Cancer Vaccine Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Type (2016-2026)
7.2 North America Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Application (2016-2026)
7.3 North America Dendritic Cell and Tumor Cell Cancer Vaccine Market Size by Country
7.3.1 North America Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume by Country (2016-2026)
7.3.2 North America Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Type (2016-2026)
8.2 Europe Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Application (2016-2026)
8.3 Europe Dendritic Cell and Tumor Cell Cancer Vaccine Market Size by Country
8.3.1 Europe Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume by Country (2016-2026)
8.3.2 Europe Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Type (2016-2026)
9.2 Asia-Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Application (2016-2026)
9.3 Asia-Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Market Size by Region
9.3.1 Asia-Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Type (2016-2026)
10.2 South America Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Application (2016-2026)
10.3 South America Dendritic Cell and Tumor Cell Cancer Vaccine Market Size by Country
10.3.1 South America Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume by Country (2016-2026)
10.3.2 South America Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Type (2016-2026)
11.2 Middle East & Africa Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Application (2016-2026)
11.3 Middle East & Africa Dendritic Cell and Tumor Cell Cancer Vaccine Market Size by Country
11.3.1 Middle East & Africa Dendritic Cell and Tumor Cell Cancer Vaccine Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Dendritic Cell and Tumor Cell Cancer Vaccine Typical Distributors
12.3 Dendritic Cell and Tumor Cell Cancer Vaccine Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Type, (USD Million), 2021-2026
Table 2. Global Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Application, (USD Million), 2021-2026
Table 3. JW CreaGene Basic Information, Manufacturing Base and Competitors
Table 4. JW CreaGene Major Business
Table 5. JW CreaGene Dendritic Cell and Tumor Cell Cancer Vaccine Product and Services
Table 6. JW CreaGene Dendritic Cell and Tumor Cell Cancer Vaccine Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Miltenyi Biotec Basic Information, Manufacturing Base and Competitors
Table 8. Miltenyi Biotec Major Business
Table 9. Miltenyi Biotec Dendritic Cell and Tumor Cell Cancer Vaccine Product and Services
Table 10. Miltenyi Biotec Dendritic Cell and Tumor Cell Cancer Vaccine Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 12. GlaxoSmithKline Major Business
Table 13. GlaxoSmithKline Dendritic Cell and Tumor Cell Cancer Vaccine Product and Services
Table 14. GlaxoSmithKline Dendritic Cell and Tumor Cell Cancer Vaccine Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. NorthWest BioTherapeutics Basic Information, Manufacturing Base and Competitors
Table 16. NorthWest BioTherapeutics Major Business
Table 17. NorthWest BioTherapeutics Dendritic Cell and Tumor Cell Cancer Vaccine Product and Services
Table 18. NorthWest BioTherapeutics Dendritic Cell and Tumor Cell Cancer Vaccine Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. ImmunoCellular Therapeutics Basic Information, Manufacturing Base and Competitors
Table 20. ImmunoCellular Therapeutics Major Business
Table 21. ImmunoCellular Therapeutics Dendritic Cell and Tumor Cell Cancer Vaccine Product and Services
Table 22. ImmunoCellular Therapeutics Dendritic Cell and Tumor Cell Cancer Vaccine Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. EnoChian Bioscience Basic Information, Manufacturing Base and Competitors
Table 24. EnoChian Bioscience Major Business
Table 25. EnoChian Bioscience Dendritic Cell and Tumor Cell Cancer Vaccine Product and Services
Table 26. EnoChian Bioscience Dendritic Cell and Tumor Cell Cancer Vaccine Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Medigene Basic Information, Manufacturing Base and Competitors
Table 28. Medigene Major Business
Table 29. Medigene Dendritic Cell and Tumor Cell Cancer Vaccine Product and Services
Table 30. Medigene Dendritic Cell and Tumor Cell Cancer Vaccine Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Tella Incorporation Basic Information, Manufacturing Base and Competitors
Table 32. Tella Incorporation Major Business
Table 33. Tella Incorporation Dendritic Cell and Tumor Cell Cancer Vaccine Product and Services
Table 34. Tella Incorporation Dendritic Cell and Tumor Cell Cancer Vaccine Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Manufacturer (2019-2021e) & (K Units)
Table 36. Global Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 37. Market Position of Manufacturers in Dendritic Cell and Tumor Cell Cancer Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 38. Global Dendritic Cell and Tumor Cell Cancer Vaccine Production Capacity by Company, (K Units): 2020 VS 2021
Table 39. Head Office and Dendritic Cell and Tumor Cell Cancer Vaccine Production Site of Key Manufacturer
Table 40. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Region (2016-2021e) & (K Units)
Table 41. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Region (2021-2026) & (K Units)
Table 42. Global Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Region (2016-2021e) & (USD Million)
Table 43. Global Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Region (2021-2026) & (USD Million)
Table 44. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Type (2016-2021e) & (K Units)
Table 45. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Type (2021-2026) & (K Units)
Table 46. Global Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Type (2016-2021e) & (USD Million)
Table 47. Global Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Type (2021-2026) & (USD Million)
Table 48. Global Dendritic Cell and Tumor Cell Cancer Vaccine Price by Type (2016-2021e) & (USD/Unit)
Table 49. Global Dendritic Cell and Tumor Cell Cancer Vaccine Price by Type (2021-2026) & (USD/Unit)
Table 50. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Application (2016-2021e) & (K Units)
Table 51. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Application (2021-2026) & (K Units)
Table 52. Global Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Application (2016-2021e) & (USD Million)
Table 53. Global Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Application (2021-2026) & (USD Million)
Table 54. Global Dendritic Cell and Tumor Cell Cancer Vaccine Price by Application (2016-2021e) & (USD/Unit)
Table 55. Global Dendritic Cell and Tumor Cell Cancer Vaccine Price by Application (2021-2026) & (USD/Unit)
Table 56. North America Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Country (2016-2021e) & (K Units)
Table 57. North America Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Country (2021-2026) & (K Units)
Table 58. North America Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Country (2016-2021e) & (USD Million)
Table 59. North America Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Country (2021-2026) & (USD Million)
Table 60. North America Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Type (2016-2021e) & (K Units)
Table 61. North America Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Type (2021-2026) & (K Units)
Table 62. North America Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Application (2016-2021e) & (K Units)
Table 63. North America Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Application (2021-2026) & (K Units)
Table 64. Europe Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Country (2016-2021e) & (K Units)
Table 65. Europe Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Country (2021-2026) & (K Units)
Table 66. Europe Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Country (2016-2021e) & (USD Million)
Table 67. Europe Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Country (2021-2026) & (USD Million)
Table 68. Europe Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Type (2016-2021e) & (K Units)
Table 69. Europe Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Type (2021-2026) & (K Units)
Table 70. Europe Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Application (2016-2021e) & (K Units)
Table 71. Europe Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Application (2021-2026) & (K Units)
Table 72. Asia-Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Region (2016-2021e) & (K Units)
Table 73. Asia-Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Region (2021-2026) & (K Units)
Table 74. Asia-Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Region (2016-2021e) & (USD Million)
Table 75. Asia-Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Region (2021-2026) & (USD Million)
Table 76. Asia-Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Type (2016-2021e) & (K Units)
Table 77. Asia-Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Type (2021-2026) & (K Units)
Table 78. Asia-Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Application (2016-2021e) & (K Units)
Table 79. Asia-Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Application (2021-2026) & (K Units)
Table 80. South America Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Country (2016-2021e) & (K Units)
Table 81. South America Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Country (2021-2026) & (K Units)
Table 82. South America Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Country (2016-2021e) & (USD Million)
Table 83. South America Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Country (2021-2026) & (USD Million)
Table 84. South America Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Type (2016-2021e) & (K Units)
Table 85. South America Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Type (2021-2026) & (K Units)
Table 86. South America Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Application (2016-2021e) & (K Units)
Table 87. South America Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Application (2021-2026) & (K Units)
Table 88. Middle East & Africa Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Country (2016-2021e) & (K Units)
Table 89. Middle East & Africa Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Country (2021-2026) & (K Units)
Table 90. Middle East & Africa Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Country (2016-2021e) & (USD Million)
Table 91. Middle East & Africa Dendritic Cell and Tumor Cell Cancer Vaccine Revenue by Country (2021-2026) & (USD Million)
Table 92. Middle East & Africa Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Type (2016-2021e) & (K Units)
Table 93. Middle East & Africa Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Type (2021-2026) & (K Units)
Table 94. Middle East & Africa Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Application (2016-2021e) & (K Units)
Table 95. Middle East & Africa Dendritic Cell and Tumor Cell Cancer Vaccine Sales by Application (2021-2026) & (K Units)
Table 96. Direct Channel Pros & Cons
Table 97. Indirect Channel Pros & Cons
Table 98. Dendritic Cell and Tumor Cell Cancer Vaccine Typical Distributors
Table 99. Dendritic Cell and Tumor Cell Cancer Vaccine Typical Customers
List of Figures
Figure 1. Dendritic Cell and Tumor Cell Cancer Vaccine Picture
Figure 2. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share by Type in 2020
Figure 3. CD 4
Figure 4. CD 8
Figure 5. HER-2
Figure 6. T-helper cell
Figure 7. Others
Figure 8. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share by Application in 2020
Figure 9. Glioblastoma Cancer
Figure 10. Prostate Cancer
Figure 11. Pancreatic Cancer
Figure 12. Colorectal Cancer
Figure 13. Renal Cancer
Figure 14. Lung Cancer
Figure 15. Others
Figure 16. Global Dendritic Cell and Tumor Cell Cancer Vaccine Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 17. Global Dendritic Cell and Tumor Cell Cancer Vaccine Market Size and Forecast (2016-2026) & (USD Million)
Figure 18. United States Dendritic Cell and Tumor Cell Cancer Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 19. Canada Dendritic Cell and Tumor Cell Cancer Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 20. Mexico Dendritic Cell and Tumor Cell Cancer Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 21. Germany Dendritic Cell and Tumor Cell Cancer Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 22. France Dendritic Cell and Tumor Cell Cancer Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 23. United Kingdom Dendritic Cell and Tumor Cell Cancer Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 24. Russia Dendritic Cell and Tumor Cell Cancer Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 25. Italy Dendritic Cell and Tumor Cell Cancer Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 26. China Dendritic Cell and Tumor Cell Cancer Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 27. Japan Dendritic Cell and Tumor Cell Cancer Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 28. Korea Dendritic Cell and Tumor Cell Cancer Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 29. India Dendritic Cell and Tumor Cell Cancer Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 30. Southeast Asia Dendritic Cell and Tumor Cell Cancer Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 31. Australia Dendritic Cell and Tumor Cell Cancer Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 32. Brazil Dendritic Cell and Tumor Cell Cancer Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 33. Egypt Dendritic Cell and Tumor Cell Cancer Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 34. Saudi Arabia Dendritic Cell and Tumor Cell Cancer Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 35. South Africa Dendritic Cell and Tumor Cell Cancer Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 36. Turkey Dendritic Cell and Tumor Cell Cancer Vaccine Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 37. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales (2016-2026) & (K Units)
Figure 38. Global Dendritic Cell and Tumor Cell Cancer Vaccine Production Capacity (2016-2026) & (K Units)
Figure 39. Global Dendritic Cell and Tumor Cell Cancer Vaccine Production Capacity by Geographic Region: 2020 VS 2021
Figure 40. Dendritic Cell and Tumor Cell Cancer Vaccine Market Drivers
Figure 41. Dendritic Cell and Tumor Cell Cancer Vaccine Market Restraints
Figure 42. Dendritic Cell and Tumor Cell Cancer Vaccine Market Trends
Figure 43. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share by Manufacturer in 2020
Figure 44. Global Dendritic Cell and Tumor Cell Cancer Vaccine Revenue Market Share by Manufacturer in 2020
Figure 45. Dendritic Cell and Tumor Cell Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 46. Top 3 Dendritic Cell and Tumor Cell Cancer Vaccine Manufacturer (Revenue) Market Share in 2020
Figure 47. Top 6 Dendritic Cell and Tumor Cell Cancer Vaccine Manufacturer (Revenue) Market Share in 2020
Figure 48. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share by Region (2016-2026)
Figure 49. Global Dendritic Cell and Tumor Cell Cancer Vaccine Revenue Market Share by Region (2016-2026)
Figure 50. North America Dendritic Cell and Tumor Cell Cancer Vaccine Revenue (2016-2026) & (USD Million)
Figure 51. Europe Dendritic Cell and Tumor Cell Cancer Vaccine Revenue (2016-2026) & (USD Million)
Figure 52. Asia-Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Revenue (2016-2026) & (USD Million)
Figure 53. South America Dendritic Cell and Tumor Cell Cancer Vaccine Revenue (2016-2026) & (USD Million)
Figure 54. Middle East & Africa Dendritic Cell and Tumor Cell Cancer Vaccine Revenue (2016-2026) & (USD Million)
Figure 55. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share by Type (2016-2026)
Figure 56. Global Dendritic Cell and Tumor Cell Cancer Vaccine Revenue Market Share by Type (2016-2026)
Figure 57. Global Dendritic Cell and Tumor Cell Cancer Vaccine Price by Type (2016-2026) & (USD/Unit)
Figure 58. Global Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share by Application (2016-2026)
Figure 59. Global Dendritic Cell and Tumor Cell Cancer Vaccine Revenue Market Share by Application (2016-2026)
Figure 60. Global Dendritic Cell and Tumor Cell Cancer Vaccine Price by Application (2016-2026) & (USD/Unit)
Figure 61. North America Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share by Country (2016-2026)
Figure 62. North America Dendritic Cell and Tumor Cell Cancer Vaccine Revenue Market Share by Country (2016-2026)
Figure 63. North America Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share by Type (2016-2026)
Figure 64. North America Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share by Application (2016-2026)
Figure 65. Europe Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share by Country (2016-2026)
Figure 66. Europe Dendritic Cell and Tumor Cell Cancer Vaccine Revenue Market Share by Country (2016-2026)
Figure 67. Europe Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share by Type (2016-2026)
Figure 68. Europe Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share by Application (2016-2026)
Figure 69. Asia-Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share by Region (2016-2026)
Figure 70. Asia-Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Revenue Market Share by Region (2016-2026)
Figure 71. Asia-Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share by Region (2016-2026)
Figure 72. Asia-Pacific Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share by Application (2016-2026)
Figure 73. South America Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share by Country (2016-2026)
Figure 74. South America Dendritic Cell and Tumor Cell Cancer Vaccine Revenue Market Share by Country (2016-2026)
Figure 75. South America Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share by Type (2016-2026)
Figure 76. South America Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share by Application (2016-2026)
Figure 77. Middle East & Africa Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share by Country (2016-2026)
Figure 78. Middle East & Africa Dendritic Cell and Tumor Cell Cancer Vaccine Revenue Market Share by Country (2016-2026)
Figure 79. Middle East & Africa Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share by Type (2016-2026)
Figure 80. Middle East & Africa Dendritic Cell and Tumor Cell Cancer Vaccine Sales Market Share by Application (2016-2026)
Figure 81. Sales Channel: Direct Channel vs Indirect Channel
Figure 82. Methodology
Figure 83. Research Process and Data Source
がん幹細胞の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Cancer stem cells (CSCs) refer to the cells obtained from tumor that posses potential to reproduce all types of cancer cells found in a cancer sample. Cancer stem cells are planned to grow in tumors as a separate population and thereby cause deterioration and metastasis of existing tumor through gen…- 小細胞肺がん治療薬の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Lung cancer can be categorized into two types: non-small cell lung cancer and small cell lung cancer. Small cell lung cancer constitutes roughly 10-15 percent of all diagnosed cases of lung cancer. Small cell lung cancer is categorized into two types: small cell carcinoma and combined small cell car…
- 循環腫瘍細胞（CTC）予後技術の世界市場予測 2023年：メーカー別、地域別、種類・用途別 Circulating tumor cells (CTCs) are specialized rare cells, which have been shed from a primary solid tumor of the body and circulate in the vasculature system of the body, eventually causing metastasis. CTCs act as the seeds for successive development of additional metastatic tumors in distant organ…
- 全細胞コレラワクチンの世界市場2018-2025 Whole Cell Cholera Vaccine is used to prevent Cholera.The factors that fuel the growth of the global whole cell cholera vaccine (recombinant B-subunit) market are rising incidence of cholera among people in endemic regions along with a lack of sanitation and hygiene in certain countries. In 2018, th…
- 世界の遺伝子組換え型チャイニーズハムスター卵巣（CHO）B型肝炎ワクチン市場 2021：企業別、地域別、種類・用途別 The Recombinant Hamster Ovary Cell (CHO) Hepatitis B Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value …